Please login to the form below
AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan
Japanese regulator clears the drug for first-line use in NSCLC
Novo spends $800m to buy biotech and 'glucose responsive insulin' tech
Ziylo could help it stay ahead in key insulin franchise
Pfizer signs mRNA flu vaccine deal with BioNTech
Pharma giant will take on development and commercial responsibility for candidates
After Cohen payment scandal, Novartis unveils new ethics chief
New 'risk and compliance' leader has increased powers
Daily Brief: Orchard raises $150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval
Gene therapy trend grows, new rival for Fabrazyme
Human Cell Atlas gets new UK funding
The project will allow researchers to define characteristics of single cell types
Spark sputters on haemophilia A gene therapy safety scare
Investors compare data unfavourably with BioMarin rival
Almirall acquires Allergan’s dermatology portfolio for $650m
The pharma group buys four products along with Allergan's first-in-class antibiotic Seysara
Immunology keeps Shire figures solid as Takeda takeover nears
Shire’s sales increased by 6% to $3.81bn
Health coverage across state lines
Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad
-
Standing out in a crowdCelltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars
-
The diseased organisationLike humans, organisations can be afflicted by genetic disorders that hinder performance and threaten survival but these can be understood and cured
-
Pfizer CEO reckons rebates will disappear, and that’s a positiveThe move also has the support of FDA Commissioner Scott Gottlieb
-
Indivior push to diversify boosted by schizophrenia drug approvalPerseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna
-
Dupixent bounce-back helps stem diabetes declines at SanofiCEO Brandicourt says Sanofi will “enter a new growth phase”
-
Nanobiotix signs €40m deal with the EIBloan to fund innovative nanomedicine platform
-
GSK: we won’t be splitting up any time soonWalmsley scotches rumours of a consumer health spin-off
-
New cancer drugs can’t quite plug the revenue hole at AZOverall sales fell 5% to $10.33bn
-
Big debate follows Biogen/Eisai’s Alzheimer’s study unveilingMixed results prompted a 10% share drop for both companies
-
Industry appointmentsVivaldi heads up Sigilon, Pfizer Oncology loses its CMO and Zelluna appoints new CSO
-
Pharma industry appointmentsDestiny Pharma, Silence Therapeutics and Concept Life Sciences add to its teams.
-
Weekly industry appointmentsGSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board
-
Biogen appoints executive VP, corporate developmentDaniel Karp will also become a member of the executive committee
-
Exelixis appoints Andrew Peters to newly created positionHe joins the biotech as its vice president, strategy
Latest sales appointments
Featured jobs
-
Medical Director
-
Excellent benefits
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Freelance Senior Account Manager – healthcare advertising
-
Employment Type:. Healthcare Advertising Jobs. Salary:. 250 to 320 per day
-
Account Manager
-
£40, 000 - £45, 000 benefits
-
Senior Medical Writer
-
Great salary and bebefits
- Senior Account Manager / Account Director
-
Great salary and bebefits
-
Scientific Director
-
Great salary and bebefits
- Account Director or Senior Account Director
-
Salary TBC
-
Market Access Consultant - Cheshire
-
Negotiable
- Multi-Channel Account Managers - Road / Homebased – Full or Part...
-
starting from £32, 500
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
-
Senior Medical Writer
-
Great salary and benefits
Subscribe to our email news alerts
- Novo’s oral diabetes drug hits the mark again
- AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan
- Envision Pharma Group relocates to support growth
- Evoke Group unveils new identity
- Roche’s Alecensa backed by China’s National Drug Administration
- FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer
PMHub
VCCP Health
We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...
Latest intelligence
- The European Medicines Agency: PRIME’d for access?
- Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
- How can pharma engage with key stakeholders on NHS service transformation?
- Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
- The race for an HIV ‘cure’
- Supercharging therapies as pharma and patients work together...
Quick links
Infographics
